Cargando…

Antineoplastics/granulocyte colony-stimulating factors: Febrile neutropenia, COVID-19, and aggravation of COVID-19 pneumonia and post-COVID-19 organising pneumonia: case report

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099340/ http://dx.doi.org/10.1007/s40278-022-14961-3

Ejemplares similares

Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors
por: Kelly, S, et al.
Publicado: (2009)

Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia
por: Advani, S. H., et al.
Publicado: (2010)

Clinical practice in febrile neutropenia risk assessment and granulocyte colony-stimulating factor primary prophylaxis of febrile neutropenia in Poland
por: Wojtukiewicz, Marek, et al.
Publicado: (2014)

Emerging cancer therapies and granulocyte-colony stimulating factor in febrile neutropenia patients presenting to the emergency department during the COVID-19 pandemic era
por: Lai, Wei-Jen, et al.
Publicado: (2023)

Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?
por: Aapro, Matti, et al.
Publicado: (2010)

Antineoplastics: COVID-19 pneumonia: 7 case reports
Publicado: (2021)

Antineoplastics: Recurrent COVID-19 pneumonia: case report
Publicado: (2021)

Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis
por: Cooper, Katy L, et al.
Publicado: (2011)

Appropriateness of granulocyte colony-stimulating factor use in patients receiving chemotherapy by febrile neutropenia risk level
por: Baig, Hassam, et al.
Publicado: (2018)

Evaluating the Prognostic Role of Monocytopenia in Chemotherapy-Induced Febrile Neutropenia Patients Treated with Granulocyte Colony-Stimulating Factor
por: Alshari, Osama, et al.
Publicado: (2021)

Continuous Intravenous Administration of Granulocyte-Colony-Stimulating Factors—A Breakthrough in the Treatment of Cancer Patients with Febrile Neutropenia
por: Căinap, Călin, et al.
Publicado: (2021)

Effects of primary granulocyte-colony stimulating factor prophylaxis on the incidence of febrile neutropenia in patients with germ cell tumors
por: Hapakova, Nikola, et al.
Publicado: (2022)

Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer
por: Aapro, Matti S., et al.
Publicado: (2023)

Antineoplastics: Cytopenia and COVID-19 pneumonia: 10 case reports
Publicado: (2021)

Granulocyte-macrophage colony stimulating factor in COVID-19: friend or foe?
por: Mehta, Puja, et al.
Publicado: (2021)

Granulocyte-macrophage colony-stimulating factor: an immunotarget for sepsis and COVID-19
por: Mu, Xiuying, et al.
Publicado: (2021)

Febrile neutropenia due to COVID-19 in an immunocompetent patient
por: Devi, Yumkham Monica, et al.
Publicado: (2021)

Antineoplastics: Prolonged viral shedding of COVID-19 pneumonia : case report
Publicado: (2021)

Risk of chemotherapy-induced febrile neutropenia in intermediate-risk regimens: Clinical and economic outcomes of granulocyte colony-stimulating factor prophylaxis
por: Aslam, Saad, et al.
Publicado: (2023)

Immunosuppressants: Hepatotoxicity, neutropenia and COVID-19 pneumonia : case report
Publicado: (2020)

Macrophage Colony‐stimulating Factor Prevents Febrile Neutropenia Induced by Chemotherapy
por: Hidaka, Takao, et al.
Publicado: (2001)

COVID-19-vaccine: Organising pneumonia: case report
Publicado: (2022)

COVID 19 and febrile neutropenia: Case report and systematic review
por: Kaya, Taner, et al.
Publicado: (2022)

Systematic Review and Meta-analysis of Short- versus Long-Acting Granulocyte Colony-Stimulating Factors for Reduction of Chemotherapy-Induced Febrile Neutropenia
por: Cornes, Paul, et al.
Publicado: (2018)

Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice
por: Averin, Ahuva, et al.
Publicado: (2020)

A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia
por: Clemons, Mark, et al.
Publicado: (2021)

Supportive therapies in the prevention of chemotherapy-induced febrile neutropenia and appropriate use of granulocyte colony-stimulating factors: a Delphi consensus statement
por: Adamo, Vincenzo, et al.
Publicado: (2022)

The Prognostic Utility of Lymphocyte-Based Measures and Ratios in Chemotherapy-Induced Febrile Neutropenia Patients following Granulocyte Colony-Stimulating Factor Therapy
por: Halalsheh, Omar M., et al.
Publicado: (2022)

Preventing healthcare-acquired infections in cancer patients with febrile neutropenia in intensive care units: The role of granulocyte-colony stimulating factor prophylaxis
por: Blot, Stijn, et al.
Publicado: (2023)

Preventing healthcare-acquired infections in cancer patients with febrile neutropenia in intensive care units: The role of granulocyte-colony stimulating factor prophylaxis
por: Chou, Hui-Chen, et al.
Publicado: (2023)

Outcomes for patients with severe chronic neutropenia treated with granulocyte colony-stimulating factor
por: Dale, David C., et al.
Publicado: (2022)

Anti-Granulocyte–Macrophage Colony–Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled Trial
por: Criner, Gerard J., et al.
Publicado: (2022)

Delayed, transient and self-resolving neutropenia following COVID-19 pneumonia
por: Mank, Victoria Marie Ferreira, et al.
Publicado: (2021)

A Multicenter Analysis of the Outcome of Cancer Patients with Neutropenia and COVID-19 Optionally Treated with Granulocyte-Colony Stimulating Factor (G-CSF): A Comparative Analysis
por: Sereno, María, et al.
Publicado: (2021)

Correction to: Systematic Review and Meta-analysis of Short-versus Long-Acting Granulocyte Colony-Stimulating Factors for Reduction of Chemotherapy-Induced Febrile Neutropenia
por: Cornes, Paul, et al.
Publicado: (2018)

Immunosuppressants: COVID-19 infection, myelosuppression and febrile neutropenia: case report.
Publicado: (2020)

The reliability of FEbrile Neutropenia after ChEmotherapy (FENCE) scores in predicting granulocyte colony-stimulating factor breakthrough febrile neutropenia among patients with lymphoma undergoing first-cycle chemotherapy: A prospective observational study
por: Thungthong, Pravinwan, et al.
Publicado: (2023)

Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed/refractory B-cell lymphoma
por: Liévin, Raphaël, et al.
Publicado: (2022)

Granulocyte Colony-stimulating Factor for Preterms with Sepsis and Neutropenia: A Randomized Controlled Trial
por: Chaudhuri, Jasodhara, et al.
Publicado: (2012)

Erratum: Anti-Granulocyte–Macrophage Colony–Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled Trial
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q1hq6mc6p8njnispdgiulo6suq